These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 30958892)

  • 1. A phase 1b study evaluating the safety and pharmacokinetics of regorafenib in combination with cetuximab in patients with advanced solid tumors.
    Weekes C; Lockhart AC; Lee JJ; Sturm I; Cleton A; Huang F; Lenz HJ
    Int J Cancer; 2019 Nov; 145(9):2450-2458. PubMed ID: 30958892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 1 dose-escalation and pharmacokinetic study of regorafenib in paediatric patients with recurrent or refractory solid malignancies.
    Geoerger B; Morland B; Jiménez I; Frappaz D; Pearson ADJ; Vassal G; Maeda P; Kincaide J; Mueller U; Schlief S; Teufel M; Ploeger BA; Cleton A; Agostinho AC; Marshall LV
    Eur J Cancer; 2021 Aug; 153():142-152. PubMed ID: 34157616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase Ib study of the combination regorafenib with PF-03446962 in patients with refractory metastatic colorectal cancer (REGAL-1 trial).
    Clarke JM; Blobe GC; Strickler JH; Uronis HE; Zafar SY; Morse M; Dropkin E; Howard L; O'Neill M; Rushing CN; Niedzwiecki D; Watson H; Bolch E; Arrowood C; Liu Y; Nixon AB; Hurwitz HI
    Cancer Chemother Pharmacol; 2019 Oct; 84(4):909-917. PubMed ID: 31444620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors.
    Mross K; Frost A; Steinbild S; Hedbom S; Büchert M; Fasol U; Unger C; Krätzschmar J; Heinig R; Boix O; Christensen O
    Clin Cancer Res; 2012 May; 18(9):2658-67. PubMed ID: 22421192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics.
    Sunakawa Y; Furuse J; Okusaka T; Ikeda M; Nagashima F; Ueno H; Mitsunaga S; Hashizume K; Ito Y; Sasaki Y
    Invest New Drugs; 2014 Feb; 32(1):104-12. PubMed ID: 23553067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of the oral multikinase inhibitor regorafenib and its association with real-world treatment outcomes.
    Fukudo M; Asai K; Tani C; Miyamoto M; Ando K; Ueno N
    Invest New Drugs; 2021 Oct; 39(5):1422-1431. PubMed ID: 33830408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study.
    Bruix J; Tak WY; Gasbarrini A; Santoro A; Colombo M; Lim HY; Mazzaferro V; Wiest R; Reig M; Wagner A; Bolondi L
    Eur J Cancer; 2013 Nov; 49(16):3412-9. PubMed ID: 23809766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603).
    Fukuoka S; Hara H; Takahashi N; Kojima T; Kawazoe A; Asayama M; Yoshii T; Kotani D; Tamura H; Mikamoto Y; Hirano N; Wakabayashi M; Nomura S; Sato A; Kuwata T; Togashi Y; Nishikawa H; Shitara K
    J Clin Oncol; 2020 Jun; 38(18):2053-2061. PubMed ID: 32343640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preliminary Safety, Pharmacokinetics, and Efficacy of Regorafenib, Cisplatin, and Pemetrexed in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancers.
    Hellmann MD; Sturm I; Trnkova ZJ; Lettieri J; Diefenbach K; Rizvi NA; Gettinger SN
    Clin Lung Cancer; 2015 Nov; 16(6):514-22. PubMed ID: 26003007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors.
    Crona DJ; Keisler MD; Walko CM
    Ann Pharmacother; 2013 Dec; 47(12):1685-96. PubMed ID: 24259629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study.
    Van Cutsem E; Martinelli E; Cascinu S; Sobrero A; Banzi M; Seitz JF; Barone C; Ychou M; Peeters M; Brenner B; Hofheinz RD; Maiello E; André T; Spallanzani A; Garcia-Carbonero R; Arriaga YE; Verma U; Grothey A; Kappeler C; Miriyala A; Kalmus J; Falcone A; Zaniboni A
    Oncologist; 2019 Feb; 24(2):185-192. PubMed ID: 30190299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase 1b study of afatinib in combination with standard-dose cetuximab in patients with advanced solid tumours.
    Gazzah A; Boni V; Soria JC; Calles A; Even C; Doger B; Mahjoubi L; Bahleda R; Ould-Kaci M; Esler A; Nazabadioko S; Calvo E
    Eur J Cancer; 2018 Nov; 104():1-8. PubMed ID: 30278378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized, double-blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer.
    Fogelman D; Cubillo A; García-Alfonso P; Mirón MLL; Nemunaitis J; Flora D; Borg C; Mineur L; Vieitez JM; Cohn A; Saylors G; Assad A; Switzky J; Zhou L; Bendell J
    Cancer Med; 2018 Nov; 7(11):5382-5393. PubMed ID: 30123970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinoma.
    Sun W; Patel A; Normolle D; Patel K; Ohr J; Lee JJ; Bahary N; Chu E; Streeter N; Drummond S
    Cancer; 2019 Mar; 125(6):902-909. PubMed ID: 30561756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study.
    Bekaii-Saab TS; Ou FS; Ahn DH; Boland PM; Ciombor KK; Heying EN; Dockter TJ; Jacobs NL; Pasche BC; Cleary JM; Meyers JP; Desnoyers RJ; McCune JS; Pedersen K; Barzi A; Chiorean EG; Sloan J; Lacouture ME; Lenz HJ; Grothey A
    Lancet Oncol; 2019 Aug; 20(8):1070-1082. PubMed ID: 31262657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regorafenib as Salvage Treatment in Korean Patients with Refractory Metastatic Colorectal Cancer.
    Kim ST; Kim TW; Kim KP; Kim TY; Han SW; Lee JY; Lim SH; Lee MY; Kim H; Park YS
    Cancer Res Treat; 2015 Oct; 47(4):790-5. PubMed ID: 25672574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors.
    Simonelli M; Zucali PA; Lorenzi E; Rubino L; De Vincenzo F; De Sanctis R; Perrino M; Mancini L; Di Tommaso L; Rimassa L; Masci G; Zuradelli M; Suter MB; Bertossi M; Fattuzzo G; Giordano L; Roncalli MG; Santoro A
    Eur J Cancer; 2013 Mar; 49(5):989-98. PubMed ID: 23146956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pazopanib plus cetuximab in recurrent or metastatic head and neck squamous cell carcinoma: an open-label, phase 1b and expansion study.
    Adkins D; Mehan P; Ley J; Siegel MJ; Siegel BA; Dehdashti F; Jiang X; Salama NN; Trinkaus K; Oppelt P
    Lancet Oncol; 2018 Aug; 19(8):1082-1093. PubMed ID: 30001987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase 1 study of regorafenib and sildenafil in adults with advanced solid tumors.
    Poklepovic AS; Gordon SW; Kothadia S; McGuire WP; Thacker LR; Deng X; Tombes MB; Shrader E; Hudson D; Bandyopadhyay D; Ryan AA; Kmieciak M; Smith S; Dent P
    Anticancer Drugs; 2024 Jun; 35(5):450-458. PubMed ID: 38452059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II Trial of Continuous Regorafenib Dosing in Patients with Gastrointestinal Stromal Tumors After Failure of Imatinib and Sunitinib.
    Kim JJ; Ryu MH; Yoo C; Beck MY; Ma JE; Kang YK
    Oncologist; 2019 Nov; 24(11):e1212-e1218. PubMed ID: 31036770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.